Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Live, attenuated influenza A virus with suppressed hemagglutinin (HA) and neuraminidase (NA) expression as a vaccine

Live, attenuated influenza A virus with suppressed HA and NA expression could be used to develop vaccines. Synthetic, attenuated virus engineering was used to insert multiple suboptimal synonymous codons into the HA and NA regions of a mouse-adapted influenza virus. In mice, the resulting influenza strain showed attenuated replication in lungs. Also in mice, inoculation with the attenuated strain induced a neutralizing antibody response and protected mice from lethal challenge with homologous or two different heterologous, mouse-adapted influenza viruses. Next steps include developing a vaccine using a non-mouse-adapted virus with suppressed HA and NA expression.

SciBX 6(24); doi:10.1038/scibx.2013.610
Published online June 20, 2013

Patent applications filed; licensed to Codagenix Inc. to develop human vaccines

Yang, C. et al. Proc. Natl. Acad. Sci. USA; published online
May 20, 2013;
doi:10.1073/pnas.1307473110
Contact: Eckard Wimmer, State University of New York at Stony Brook, Stony Brook, N.Y.
e-mail:

eckard.wimmer@stonybrook.edu
Contact: Steffen Mueller, same affiliation as above
e-mail:

steffen.mueller@stonybrook.edu